| Autor: |
Crowell EB Jr; Mary Babb Randolph Cancer Center, West Virginia University School of Medicine, Morgantown, USA., Jubelirer SJ |
| Jazyk: |
angličtina |
| Zdroj: |
The West Virginia medical journal [W V Med J] 2000 Nov-Dec; Vol. 96 (6), pp. 598-601. |
| Abstrakt: |
Breast cancer is a major health concern for women in the U.S. Several factors determine a woman's risk for developing breast cancer including age, genetics, hormonal exposure and others. It is possible to estimate a woman's risk for developing breast cancer by using a statistical model known as the Gail model. Using this model, the Breast Cancer Prevention Trial (BCPT) found that women at high risk for breast cancer could have their incidence of breast cancer reduced by 49% by taking tamoxifen. The serious side effects of tamoxifen therapy were almost exclusively seen in women over age 50. Women under 50 with a high risk of breast cancer are, therefore, most likely to benefit from taking tamoxifen for five years. Thus, a benefit-to-risk estimate should be made for each woman before advising her to take tamoxifen. A new trial (Study of Tamoxifen And Raloxifene, STAR) will compare tamoxifen with raloxifene for their effectiveness in reducing breast cancer and for side effects. West Virginia women participated in the BCPT and will be able to participate in the STAR trial through centers in Morgantown and Charleston. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
